Results for tag: "Hepatic Encephalopathy Drug"

Hepatic Encephalopathy (HE) is a neurological disorder caused by liver failure. It is characterized by a range of neurological symptoms, including confusion, disorientation, and coma. Treatment of HE typically involves the use of drugs that act on the Central Nervous System (CNS). These drugs are used to reduce the symptoms of HE and improve the patient's quality of life. Commonly used CNS drugs for HE include benzodiazepines, anticonvulsants, and antipsychotics. The Hepatic Encephalopathy Drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of liver diseases, such as cirrhosis and hepatitis, and the need for effective treatments. The market is expected to continue to grow in the coming years, as new treatments are developed and more patients are diagnosed with HE. Some of the major companies in the Hepatic Encephalopathy Drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more